Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines

European Journal of Pharmaceutical Sciences

Volumn 11, Issue 3, 2000, Pages 207-214

  Van Der Sandt, Inez C J ^a   Blom Roosemalen, Margret C M ^a   De Boer, Albertus G ^a   Breimer, Douwe D ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Caco 2; Doxorubicin; LLC PK1; LLC PK1:MDR1; Organic cation carrier systems; P glycoprotein; Rhodamine 123

Indexed keywords

CARRIER PROTEIN; CIMETIDINE; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; QUININE; RHODAMINE 123; TETRYLAMMONIUM; VALSPODAR; VERAPAMIL;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CELL TRANSPORT; CELL TYPE; CONTROLLED STUDY; DRUG TRANSPORT; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KIDNEY CELL; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE; CELL POLARITY; CIMETIDINE; CYCLOSPORINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; EPITHELIAL CELLS; HUMANS; KINETICS; LLC-PK1 CELLS; P-GLYCOPROTEIN; RHODAMINE 123; SWINE; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0033862088     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00097-X     Document Type: Article

References (23)

1. Beck W.T., Cirtain M.C., Glover C.J., Felsted R.L., Safa A.R. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem. Biophys. Res. Commun. 153:1988;959-966.
2. Chaudhary P.M., Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic cells. Cell. 66:(1):1991;85-94.
3. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human and tumour tissues. J. Histochem. Cytochem. 38:1990;1277-1287.
4. De Lange E.C.M., De Bock G., Schinkel A.H., De Boer A.G., Breimer D.D. BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm. Res. 15:(11):1998;1657-1665.
5. Denis-Gay M., Petit J.M., Ratinaud M.H. Rhodamine 123: is it an appropriate dye to study P-glycoprotein activity in adriamycin-resistant K562 cells. Anticancer Res. 15:(1):1995;121-126.
6. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
7. Hosoya K., Kim K.J., Lee V.H.L. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm. Res. 13:(6):1996;885-890.
8. Higgins C.F. ABC transporters, from microorganisms to man. Annu. Rev. Cell Biol. 8:1992;67-113.
9. Kim R.B., Fromm M.F., Wandel C., Leade B., Wood A.J.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Inv. 101:(2):1998;289-294.
10. Masereeuw R., Moons M.M., Russel F.G.M. Rhodamine-123 accumulates extensively in the isolated perfused rat kidney and is secreted by the organic cation system. Eur. J. Pharm. 312:1997;315-323.
11. Nare B., Prichard R.K., Georges E. Characterization of rhodamine-123 binding to P-glycoprotein in human multidrug-resistant cells. Mol. Pharmacol. 45:1994;1145-1152.
12. Pétriz J., O'Connor J.E., Carmona M., García-López J. Is rhodamine-123 an appropriate fluorescent probe to assess P-glycoprotein mediated multidrug resistance in vinblastine-resistant CHO cells? Anal. Cell. Pathology. 14:1997;129-140.
13. Safa A.R., Robert S., Agresti M., Fine R.L. Tamoxyfen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells. Biochem. Biophys. Res. Commun. 202:1994;606-612.
14. Sasaya M., Wada I., Shida M., Sata M., Hatakeyama Y., Saitoh H., Takada M. Uptake of doxorubicin by cultured kidney epithelial cells LLC-PK1. Biol. Pharm. Bull. 21:(5):1998;527-529.
15. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251:1998;252-261.
16. Schinkel A.H., Smit J.J.M., Van Tellingen O., Beijnen J.H., Wagenaar E., Van Deemter L., Mol C.A.A.M., Van der Valk M.A., Robanus-Maandag E.C., Te Riele H.P.J., Berns A.J.M., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensitivity to drugs. Cell. 77:1995;491-502.
17. Schinkel A.H., Wagenaar E., Van Deemter L., Mol C.A.A.M., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:(4):1995;1698-1705.
18. Schinkel A.H., Wagenaar E., Mol C.A.A.M., Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:(11):1996;2517-2524.
19. Shapiro A.B., Fox K., Lam P., Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone - Evidence for a third-binding site. Eur. J. Biochem. 259:(3):1999;841-850.
20. Smit J.W., Duin E., Steen H., Oosting R., Roggeveld J., Meijer D.K. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br. J. Pharm. 123:(3):1998;361-370.
21. Twentyman P.R., Rhodes T., Rayner S. A comparison of rhodamine-123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur. J. Cancer. 30A:(9):1994;1360-1369.
22. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T., Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267:(34):1992;24 248-24 252.
23. Zhang X., Collins K.I., Greenberger L.M. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1. J. Biol. Chem. 270:1995;5441-5448.